Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jan 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat osteosarcoma, a type of bone cancer, by looking closely at the tumor's environment and its genetic makeup. Researchers have discovered different types of tumor environments that can affect how well patients respond to treatments like immunotherapy. In this study, doctors will analyze biopsy samples from patients with osteosarcoma to identify these tumor environment types. This information will help them create personalized treatment plans if the cancer progresses.

To be eligible for the trial, patients should have suspected osteosarcoma with enough medical evidence, have tumors that can be observed or removed, and be scheduled for surgery to provide tissue samples for analysis. The trial is not yet recruiting participants, but once it begins, those involved can expect thorough assessments of their tumors and potential access to tailored treatment strategies based on their unique tumor environment. Overall, this study aims to improve outcomes for osteosarcoma patients by using advanced techniques to guide their care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information;
• • (ii) patients who have evaluable lesions to resect or follow;
• • (iii) patients who are planned to be operate with enough flesh specimens for this study.
• Exclusion Criteria:
• • (i) clinical information was not complete;
• • (ii) lost to follow-up.